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Characterising the nicotine 
metabolite ratio and its association 
with treatment choice: A cross 
sectional analysis of Stop Smoking 
Services in England
Lion Shahab  1,2, Emily Mortimer1, Linda Bauld2,3, Jennifer A. McGowan1, Ann McNeill2,4  
& Rachel F. Tyndale5
Pharmacotherapy provision based on Nicotine Metabolite Ratio (NMR) status (slow/normal 
metabolism) may improve smoking cessation rates. However, it is unclear whether NMR status 
is consistent across patient characteristics and current treatment choice. Data come from 1,826 
participants attending Stop Smoking Services (SSS) across England in 2012/13. Sociodemographic, 
mental/physical health, smoking and treatment characteristics (nicotine replacement therapy vs. 
other pharmacotherapy; group vs. one-to-one behavioural support) were assessed. Salivary nicotine 
metabolites were measured and NMR (3-hydroxycotinine/cotinine) computed, characterising smokers 
as slow (NMR < 0.31) or normal (NMR ≥ 0.31) metabolisers. Normal metabolisers were older than 
slow metabolisers (Odds Ratio (OR) = 1.49, 95% Confidence Interval (CI) = 1.32–1.69) but no other 
characteristics were associated with NMR status. Overall, predictors accounted for only 7.3% of NMR 
variance. In adjusted analysis, pharmacotherapy type was not associated with NMR status, but normal 
metabolisers were less likely to use group support (OR = 0.67, 95% CI = 0.51–0.89). NMR status does 
not vary substantially across sociodemographic characteristics. Given its impact on pharmacotherapy 
efficacy, the lack of an association with pharmacotherapy choice suggests there is scope to use NMR 
status to optimise the selection and efficacy of smoking cessation pharmacotherapy. The unexpected 
association of NMR status with behavioural support should be explored further.
Tobacco use remains a major global health and economic burden, resulting in the premature death of 78,000 
smokers in England every year1. The principal aim of the National Health Service’s (NHS) ‘Stop Smoking Services’ 
(SSS) is to provide high-quality, evidence-based smoking cessation interventions to smokers seeking treat-
ment2. While approximately 270,000 quit dates are being set each year through these services alone3, current 
CO-validated 4-week cessation rates are 36%1, highlighting a need for improvement.
An emerging method for improving cessation outcomes is the personalisation of treatment based on validated 
biomarkers4. One such biomarker is the nicotine metabolite ratio (NMR) – a phenotypic surrogate of nicotine 
clearance5. Nicotine is predominantly metabolised by the liver enzyme CYP2A66 into cotinine, and subsequently 
exclusively by CYP2A6 into 3′hydroxycotinine7. As 3-hydroxycotinine is formation dependent and cotinine has 
a long half-life, among regular smokers the ratio of 3′hydroxycotinine to cotinine - the NMR - is stable, and 
independent of time of last cigarette8. Due to the prominent role of CYP2A6 in nicotine clearance, the NMR is 
also a biomarker of total nicotine clearance5. The NMR is stable over time8–10, and multiple clinical trials have 
identified differential quit rates for different pharmacotherapies among normal or fast compared with slower 
1Department of Behavioural Science and Health, University College London, London, UK. 2UK Centre for Tobacco 
and Alcohol Studies, Nottingham, UK. 3School of Health Sciences, University of Stirling, Scotland, Stirling, UK. 
4Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, 
UK. 5Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) and 
Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. 
Correspondence and requests for materials should be addressed to L.S. (email: lion.shahab@ucl.ac.uk)
Received: 12 September 2017
Accepted: 4 December 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIFIC REPORTS | 7: 17613  | DOI:10.1038/s41598-017-17994-8
metabolisers11–15. As NMR incorporates both genetic and environmental influences, it provides a surrogate of 
nicotine clearance which extends beyond CYP2A6 genotypic measures16. It can also be analysed relatively easily 
from plasma or saliva samples and therefore holds potential clinical utility as a predictive biomarker for cessation 
outcomes17.
The clinical utility of NMR may be further understood through examination of its effectiveness, accessibility, 
and appropriateness within clinical practice18. NMR status (dividing smokers into slow vs. normal metabolisers) 
has recently been used to prospectively evaluate the efficacy of varenicline versus nicotine patch smoking ces-
sation treatment15. Varenicline, compared with NRT, was associated with an increased quit rate among normal 
but not among slow metabolisers15. Lower abstinence rates have also been observed in retrospective analyses of 
fast or normal metabolisers, compared with slower metabolisers, with the use of NRT patch11,12,14,19. In addition, 
normal compared with slow metabolisers display lower quit rates with behavioural counselling alone13,20. Such 
studies suggest that personalising cessation treatment using the NMR status may be an efficacious and appropri-
ate method of improving the success of attempts to stop smoking.
However, the selection of smoking cessation treatment in naturalistic settings has not yet been explored in 
relation to NMR status. While NRT aims to reduce withdrawal symptoms by substituting the nicotine source21, 
varenicline both reduces nicotine craving and blocks the rewarding effects of smoking22. Given that higher NMR 
has been associated with greater cigarette craving19 and withdrawal during a quit attempt23,24, it is possible that 
smokers are self-selecting the most appropriate cessation aid. That is, over several quit attempts, smokers may 
learn which pharmacotherapy benefits them most, or stop smoking advisors may already recommend the most 
appropriate treatment based on characteristics associated with NMR, such as dependence. Further understanding 
of smokers’ current treatment use would therefore facilitate our understanding of the potential efficacy of the 
NMR as a biomarker for personalising cessation treatment. For example, as normal metabolisers show greater 
cessation rates with the use of varenicline, versus nicotine patch15, a null association between NMR and treatment 
choice would suggest that attaining a pre-treatment measure of NMR might improve the selection of – and there-
fore efficacy of - pharmacological smoking cessation treatment.
In order to further assess the potential suitability of NMR within clinical practice, the reliability of the bio-
marker with a proposed cut-off to identify slow and normal metabolisers must be considered. While a num-
ber of factors, including age25,26, ethnicity27,28, sex29, and nicotine dependence30 have been associated with 
inter-individual variability in NMR, no studies have looked at the association of these factors with NMR status 
(slow vs normal) and only one clinical trial has explored the association between NMR (but again not NMR sta-
tus) and multiple sources of variation simultaneously16. This is important as any treatment offered will depend 
on classification into NMR status (e.g. slow vs. normal) and if such characteristics significantly impacted NMR 
status, this would undermine its clinical utility as an independent marker of treatment success across a range of 
socio-demographic confounders. As with other clinical markers, an appropriate cut-off point would distribute 
these characteristics evenly across categories. Moreover, associations with continuous NMR may be statistically 
significant but not clinically meaningful and in practice vary little by dichotomous NMR status. So far, a range 
of demographic and environmental factors were found to have little impact on NMR variation, supporting the 
feasibility of the biomarker as a prospective guide for pharmacological treatment. Replication and extension of 
these findings in other populations (treatment-seeking smokers) and geographic locations using NMR status is 
now required. For instance, the association of NMR with mental health status has yet to be explored, despite the 
increased prevalence of smoking within populations with mental health conditions31.
In a large sample of treatment seekers in the UK, the present study therefore aimed to:
 1) characterise NMR and NMR status in terms of its association with sociodemographic, smoking, health-re-
lated, and treatment characteristics and,
 2) explore the relationship between NMR status and treatment choice for smoking cessation, including 
pharmacotherapy.
Materials and Methods
Participants and Procedure. Data from the ‘Evaluating Long-term Outcomes of NHS Stop Smoking 
Services’ (ELONS) study, a prospective observational examination of 3,045 participants accessing SSS, were 
used. Participants were recruited between March 2012 and March 2013 from nine regions across England. All 
participants provided informed consent to take part in this study. Further details regarding the methodology 
can be found elsewhere32. Eligible participants consisted of SSS clients who were not pregnant, were aged 16 or 
above, and who were willing to provide a saliva sample before cessation treatment began. Additional funding was 
attained to collect saliva samples upon registration with the SSS33. The majority of participants (61.6%, N = 1,875) 
provided a saliva sample. Those providing a sample were younger, less likely to be female, white British or choose 
varenicline32. They were also more likely to choose group behavioural support. There were no other demographic 
or treatment differences.
Saliva samples, sociodemographic, smoking, health-related, and treatment characteristics were recorded by 
NHS SSS staff prior to treatment. Saliva samples were collected on the first clinic visit, prior to setting a quit date, 
with Sarstedt Salivettes®, posted to University College London and stored in −20 °C freezers. Saliva samples were 
subsequently shipped to the University of Toronto (N = 1,626) or ABS laboratory (N = 249) for analysis. As an 
interlaboratory comparison of 100 randomly selected samples assayed at both laboratories showed very high cor-
relation (ρ = 0.91), results from both labs were pooled in this analysis. Ethical approval for the study was provided 
by the South East Scotland Research Ethics Committee (11/AL/0256) and research complied with the ethical 
principles on human research, as per the Declaration of Helsinki.
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Measures. Sociodemographic measures. Age, sex, ethnicity, and socioeconomic status (SES) were assessed 
using the ELONS prospective study baseline data collection questionnaire32. Due to the limited number of par-
ticipants from ethnic minority groups, a binary split was used to compare those identifying as White British to 
all other ethnicities.
The reduced National Statistics Socio-economic Classification (NSSEC) was used as a measure of SES. This 
conceptualises social class based on occupation/ employment status and has been validated in a number of UK 
samples34, and as a predictor of smoking cessation success35. SES was further grouped into higher vs. lower SES, 
using the NSSEC coding ABC1/C2DE (managerial occupations/manual and unemployed).
Smoking Characteristics. Nicotine dependence was measured using the Heaviness of Smoking Index (HSI); a 
measure of time to first cigarette and cigarettes per day36. Participants with a score ≥4 (out of 6), were classified 
as having high dependence and compared with those with low dependence (<4)37. Determination to quit was 
measured using one item rated with a 4-point Likert scale (ranging from ‘not at all determined’ to ‘extremely 
determined’) and participants were also asked if they had attempted to quit in the past 12 months (yes/no).
Health-related measures. Physical health was assessed using one item; participants selected any applicable med-
ical conditions. Those with at least one medical condition were coded as having poorer physical health, compared 
with those without. Psychological wellbeing was measured using the WHO-5 wellbeing index38. The scale has 
been credited with reasonable validity, as a method of assessing depression and as an outcome for clinical trials39. 
Participants were scored on a scale of 1–25 (25 representing the highest quality of life), and scores were multiplied 
by 4 to attain a percentage. A score ≤50% was used to indicate low subjective wellbeing39.
Stop Smoking Service. Given the likely relationship between treatment choice and SSS location40, this was 
recorded by the relevant practitioners during baseline data collection. For ease of interpretation SSS were divided 
into North, Midlands and South regions of England.
Nicotine Metabolite Ratio. Saliva samples were analysed for cotinine (COT) and trans-3′-hydroxycotinine 
(3HC) levels using an established LC-MS/MS methodology with a 1 ng/mL limit of quantification (LOQ)17,41. The 
NMR ratio of 3HC/COT was then determined. The ratio has been shown to remain stable over time of day8, over 
a period of months10 and while contemplating quitting9. Data were examined for analytical shift and reliability, 
using a reanalysis of samples from each batch (approximately 5% of samples). NMR between replicate analyses 
was highly correlated (R2 = 0.984), there was no association between change in NMR and time between analy-
ses (R2 = 0.004) and the percent of difference between analysis replicates varied by less than 10%. Samples with 
cotinine values below 10 ng/ml were excluded as they likely reflect occasional or light smokers, where the NMR 
may be unstable. For samples in which COT was above 10 ng/ml, and 3HC was below the limit of quantification, 
as per convention, the 3HC value was replaced by a dummy value of 0.71 (LOQ/sqrt2) and included in the NMR 
(i.e. NMR = 0.71/COT)42. As plasma and salivary NMR are highly correlated5, we used a cut-off for plasma NMR 
from a previous clinical trial based on population data15 to stratify participants into normal (NMR ≥ 0.31) or slow 
(NMR < 0.3) salivary metabolising status.
Treatment characteristics. As this was an observational study, participants were free to choose their treatment 
after consultation with a SSS practitioner. The elected pharmacotherapy and behavioural support type were 
recorded by the practitioner. Pharmacotherapy was dichotomised into non-NRT (varenicline or bupropion; these 
groups were combined as the bupropion sample was too small) vs. NRT product use (single or combined); those 
receiving no pharmacotherapy and those using NRT with varenicline or bupropion were excluded from analy-
ses of pharmacotherapy. Behavioural support was divided into individual (one-to-one; non-group drop-in) vs. 
group-based (open/rolling groups; closed groups) support.
Analyses. Univariate associations between NMR status and sociodemographic, smoking, health-related, and 
treatment characteristics were assessed using chi-square/t-tests for categorical/continuous variables, respectively. 
A multi-variable logistic regression was used to explore independent relationships between NMR status (normal 
vs. slow metabolisers) and each of the sociodemographic, smoking, and health-related characteristics. Separate 
regression models were used to assess the association between NMR status and pharmacotherapy choice and 
behavioural support type, controlling for all other covariates. As age did not meet the linearity assumption, it was 
transformed using the standard deviation of the variable as the scaling factor, and entered into the model as a 
continuous variable43. Similarly, where NMR was treated as a continuous variable, it was log-transformed due to 
significant non-normality. Sensitivity analyses were conducted using stepwise regression models (backward and 
forward methods), using NMR as a continuous variable and restricting the NRT sample to NRT patch-only users 
and non-NRT users to varenicline-only users, given that previous work has focused on these. Main analyses were 
also repeated defining NMR status by quartiles of individuals (slow metabolisers in first quartile [N = 458] vs. fast 
metabolisers in forth quartile[N = 452]) and including an NMR status by last year quit attempt interaction term, 
based on the rationale that individuals may self-select treatment based on experiences with treatment during 
recent prior quit attempts.
Data availability. Anonymised datasets generated during and/or analysed during the current study are avail-
able from the corresponding author on reasonable request.
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Results
Participants characteristics and association with NMR and NMR status. Of the 1,875 participants 
for whom saliva samples were obtained, 44 provided samples that contained insufficient saliva or were below the 
limit of quantification and 5 samples were lost in the post, resulting in 1,826 participants included in the final 
analysis (Fig. 1). The geometric mean (gM) NMR for all participants was 0.41 (95% Confidence Interval (CI) 
0.40–0.42). Of these, 71.5% (N = 1306) were normal (gM = 0.53, 95%CI 0.52 = 0.55) and 28.5% (N = 520) were 
slow (gM = 0.21, 95%CI 0.20–0.21) metabolisers.
The majority of the sample was white, female and in the C2DE SES group (Table 1). High cigarette dependence 
was seen in approximately half the sample and most participants reported being extremely or very determined to 
quit. Just under half had attempted to quit in the previous year and just over half were identified as having poorer 
psychological wellbeing and/ or poorer physical health (at least one medical condition). Most participants used 
either NRT or varenicline during their quit attempt and around half sought one-to-one support.
There were some differences between normal and slow metabolisers (Table 1). Normal metabolisers were on 
average older, more likely to be white, from lower SES groups, with greater cigarette dependence and poorer phys-
ical health and psychological wellbeing. However, in adjusted logistic regression analysis, only older age remained 
a significant predictor of being a normal metaboliser (adj OR 1.49; 95%CI 1.32–1.69; Table 2), with the model 
accounting for 6.7% of the overall variance in NMR status. In sensitivity analysis using NMR as a continuous 
variable, the linear regression model explained a similarly small amount of variance (7.3%). Moreover, in addition 
to older age (B 0.12, 95%CI 0.09–0.15), having a medical condition (B 0.10, 95%CI 0.05–0.16) and being of white 
ethnicity (B 0.12, 95%CI 0.00–0.24) and female (B = 0.05, 95%CI 0.00–0.11) were also independently associated 
with a higher NMR (Table 2).
Association of NMR status with treatment choice. Results of the regression models exploring adjusted 
associations of choice of pharmacotherapy type (varenicline/bupropion vs. NRT) and behavioural support type 
(individual vs. group) with NMR status are presented in Table 3. NMR status was not significantly associated 
with pharmacotherapy choice. However, relative to slow metabolisers, normal metabolisers were significantly 
less likely to choose group behavioural support (OR = 0.67, 95%CI = 0.51–0.89). The models explained 9% and 
30% of the variance in treatment choice, respectively. Sensitivity analyses using stepwise regression models and 
using NMR as a continuous variable confirmed these results. No interactions between NMR and SSS on treatment 
choice were identified, and the lack of association between NMR status or NMR with pharmacotherapy choice 
was not materially altered when restricting the NRT sample to NRT patch-only users and the non-NRT sample 
to varenicline-only users. Repeating the main analysis when defining NMR status by quartiles (fast metabolisers 
[forth quartile] vs slow metabolisers [first quartile]) confirmed results: NMR status was not associated with phar-
macotherapy choice (adj OR 0.98; 95%CI 0.88–0.1.06) but relative to slow metabolisers, fast metabolisers were 
significantly less likely to choose group behavioural support (adj OR 0.81; 95%CI 0.72–0.92). Lastly, there was no 
significant interaction between NMR status and last year quit attempts on either pharmacotherapy or behavioural 
support treatment choice.
Discussion
This study set out to characterise NMR and NMR status in terms of its association with sociodemographic, smok-
ing, and health-related characteristics and to examine the association between pharmacological/behavioural 
treatment choice and NMR. Normal vs slow nicotine metabolism was found to be associated with older age, and 
NMR was also linearly associated with being white, female and having a medical condition but with no other 
Figure 1. Nicotine metabolite ratio (NMR) by NMR status. Boxplots show median with interquartile range, 
IQR (25–75%); error bars show Tukey’s whiskers and cross indicates arithmetic mean (geometric means are 
provided in text); Solid grey circles show outliers.
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characteristics. Regarding treatment choice, normal NMR status was associated with a reduced likelihood of 
receiving group behavioural support but not with pharmacological treatment choice.
This study confirms previous research showing a positive association between age and NMR26. As it is unlikely 
NMR increases with age, given that there is no association of age (within adults) with hepatic levels of CYP2A6, 
the enzyme involved in nicotine and cotinine metabolism, and no impact of age on in vivo nicotine or coumarin 
(a CYP2A6 probe substrate) metabolism44, this probably reflects selection bias. That is, it is possible that the 
greater difficulty in stopping smoking observed in individuals with a normal nicotine metabolism20,45,46 results 
in an increased number of older smokers in this normal NMR subgroup. If this is the case, age would be unlikely 
to influence the reliability of the biomarker given the suggested direction of the relationship. The fact that age but 
not poor health remains independently associated with NMR status also suggests self-selection, given that the 
association of poor health is likely due to the greater number of comorbidities observed in older smokers.
The study also confirms previously observed associations of higher NMR (though not NMR status) with 1) 
being female, likely due to estrogen effects on inducing CYP2A6, and 2) being of white/Caucasian ethnicity due 
to a lower frequency of reduced- and loss-of function variants in Caucasians16,47–49. It is unclear why continuous 
NMR (but not categorised NMR status) remains associated with poor physical health, even after controlling 
for age, and perhaps this reflects some underlying independent genetic association, power issues or artefactual 
confounding. However, as these characteristics were not related to NMR status and did not differentiate between 
slow vs. normal metabolisers, explaining less than 8% of the overall variance in NMR, this underlines the clinical 
utility of NMR status as a consistent and reliable marker across different populations.
This study also set out to explore the relationship between NMR status and treatment choice. No association 
between NMR status and the use of either non-NRT or NRT-based pharmacotherapy was detected (including 
NRT patch alone), implying that there is no treatment self-selection as a function of NMR status. This is further 
confirmed by the fact that experience of recent quit attempts did not affect the association (or lack thereof) of 
NMR status with treatment choice. Given the improved effectiveness of non-NRT over NRT-based pharmaco-
therapy in normal but not slow metabolisers15, this suggests there is room to improve treatment outcomes by 
personalising treatment. Specifically, as the numbers needed to treat reduces from 26 to 5 for NRT to non-NRT 
pharmacotherapy in normal metabolisers, this group could be treated preferentially with varenicline, bupropion 
or similar medication, something which is currently not the case. Good quality clinics may want to explore their 
capacity to test for this biomarker when assessing clients as a way of informing pharmacotherapy choice
Interestingly, normal metabolisers were less likely to choose group behavioural support. As normal metab-
olizers were on average older, we analysed the data both as a confounder (Table 3) and as an age by NMR status 
Total 
(N = 1,826)
Normal NMR 
(N = 1,306)
Slow NMR 
(N = 520) P
Mean (SD) age 41.7 (14.1) 43.4 (14.0) 37.5(13.6) <0.001
% (N) Female 52.7 (963) 53.8 (703) 50.0 (260) 0.15
% (N) Higher SES (ABC1) 23.9 (436) 22.6 (295) 27.1 (141) 0.04
% (N) White 95.0 (1,735) 95.8 (1251) 93.1 (484) 0.03
% (N) Higher dependence score (HSI ≥ 4)* 48.5 (879) 50.3 (650) 44.1 (229) 0.02
% (N) Determination to quit† 0.11
  Not at all 8.9 (157) 9.7 (123) 6.7 (34)
  Very determined 42.7 (757) 42.8 (541) 42.6 (216)
  Extremely determined 48.4 (857) 47.5 (600) 50.7 (257)
% (N) Last year quit attempt‡ 41.2 (730) 41.5 (525) 40.7 (205) 0.79
% (N) Poor physical health 55.9 (1,020) 59.1 (772) 47.7 (248) <0.001
% (N) Poor wellbeing§ 56.8 (992) 58.5 (729) 52.6 (263) 0.03
% (N) Pharmacological support 0.53
  Single NRT 15.6 (284) 15.6 (204) 15.4 (80)
  Combination NRT 33.7 (615) 33.9 (443) 33.1 (172)
  Varenicline 41.2 (753) 40.6 (530) 42.9 (223)
  Bupropion 1.0 (18) 1.0 (13) 1.0 (5)
  Varenicline and NRT 4.9 (89) 4.7 (61) 5.4 (28)
  Other combination 0.2 (3) 0.2 (3) 0.0 (0)
  None 3.5 (64) 4.0 (52) 2.3 (12)
% (N) Group behavioural support 0.06
  Closed group 4.5 (83) 3.8 (49) 6.5 (34)
  Open group 19.4 (354) 18.8 (245) 21.0 (109)
  Drop-in clinic 25.2 (461) 26.1 (341) 23.1 (120)
  One-to-one support 50.5 (922) 51.1 (667) 49.0 (255)
  Other 0.3 (6) 0.3 (4) 0.4 (2)
Table 1. Baseline characteristics by nicotine metabolite ratio (NMR) status. HSI = Heaviness of Smoking Index; 
SES = socioeconomic status; *14 cases missing; †55 cases missing; ‡56 cases missing; §80 cases missing
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interaction term (not significant), suggesting age was not the explanation. Slower compared with faster metab-
olisers have been reported to benefit more from behavioural counselling alone13,20. While the cause of this rela-
tionship is largely unknown, normal or fast nicotine metabolism has been linked with longer smoking duration46, 
increased cigarette craving during a quit attempt19,20,50, and greater nicotine dependence37. Given the greater dif-
ficulty in stopping smoking in this group, it could therefore be speculated that normal metabolisers may perceive 
an additional benefit from individual support compared with group support, which allows for flexible consulta-
tions that can be tailored to the clients personal situation and their experience of previous quit attempts51. In addi-
tion, the increased need for pharmacotherapy in this group may underlie this association as pharmacotherapy is 
more likely to be accessed via community practitioners (e.g. General Practitioners, pharmacists) who predomi-
nantly offer individual support. By contrast, specialist stop smoking clinics provide a range of behavioural sup-
port including group counselling which may not always involve pharmacotherapy32. Overall, however, the study 
that provided our data found that group support was more effective in supporting smokers to quit32, which may 
Pharmacotherapy type* N = 1,579‡ Behavioural support type† N = 1,717§
Adj. OR (95%CI) P Adj. OR (95%CI) P
Normal NMR (ref. slow) 0.96 (0.76–1.21) 0.74 0.67 (0.51–0.89) 0.005
Age 0.92 (0.82–1.03) 0.12 0.93 (0.81–1.07) 0.31
Female (ref. male) 0.83 (0.67–1.02) 0.07 0.94 (0.73–1.21) 0.64
Higher SES/ ABC1 (ref. C2DE) 1.53 (1.20–1.95) 0.001 1.10 (0.82–1.47) 0.53
White ethnicity (ref. other ethnicity) 5.14 (2.71–9.74) <0.001 1.19 (0.57–2.49) 0.65
Higher dependence/HSI ≥ 4 (ref. HSI < 4) 1.10 (0.89–1.36) 0.36 1.27 (0.99–1.64) 0.07
Determination to quit
   Very (ref. not determined) 0.89 (0.60–1.30) 0.53 0.63 (0.41–0.98) 0.04
   Extremely (ref. not determined) 0.95 (0.65–1.40) 0.74 0.66 (0.43–1.02) 0.06
Last year quit attempt (ref. no attempt) 1.02 (0.82–1.25) 0.89 0.93 (0.72–1.20) 0.55
Poor physical health (ref. good physical health) 0.69 (0.55–0.86) 0.001 1.14 (0.87–1.48) 0.35
Poor wellbeing/WHO score ≤ 50%  
(ref. WHO score > 50%) 0.78 (0.63–0.97) 0.02 0.71 (0.55–0.92) 0.009
SSS Region
   South (ref. North) 1.50 (1.09–2.07) 0.012 5.52 (3.50–8.71) <0.001
   Midlands (ref. North) 1.73 (1.38–2.16) <0.001 15.6 (10.8–22.4) <0.001
Table 3. Associations between treatment choice and participant characteristics. *Varenicline/bupropion 
vs. nicotine replacement therapy (reference); †Group support vs. individual support (reference); ‡Excludes 
cases with incomplete data (N = 103) and/or those with either NRT and varenicline/bupropion combination 
use (N = 86) or no pharmacotherapy use (N = 58); §Excludes cases with incomplete data (N = 103) and/
or those with ‘other’ behavioural support (N = 6); Adj. OR = adjusted odds ratio (adjusted for all variables 
shown); CI = confidence interval; NMR = Nicotine metabolite ratio; HSI = Heaviness of Smoking Index; 
SES = socioeconomic status; SSS = Stop Smoking Services; ref. = reference category.
NMR N = 1723* NMR status (Normal vs. slow metabolisers) N = 1723*
B (95%CI) P Adj. OR (95%CI) P
Age 0.12 (0.09–0.15) <0.001 1.49 (1.32–1.69) <0.001
Female (ref. male) 0.05 (0.00–0.11) 0.05 1.16 (0.93–1.44) 0.19
Higher SES/ABC1 (ref. C2DE) −0.04 (−0.10–0.02) 0.18 0.84 (0.66–1.08) 0.17
White ethnicity (ref. other ethnicity) 0.12 (0.00–0.24) 0.05 1.47 (0.93–2.34) 0.10
Higher dependence/HSI ≥ 4 (ref. HSI < 4) 0.03 (−0.02–0.09) 0.20 1.18 (0.94–1.46) 0.15
Determination to quit
  Very (ref. not determined) 0.01 (−0.09–0.10) 0.91 0.77 (0.50–1.18) 0.24
  Extremely (ref. not determined) −0.02 (−0.12–0.07) 0.57 0.73 (0.48–1.11) 0.16
Last year quit attempt (ref. no attempt) 0.03 (−0.03–0.08) 0.35 1.12 (0.90–1.40) 0.31
Poor physical health (ref. good physical 
health) 0.10 (0.05–0.16) <0.001 1.22 (0.97–1.53) 0.09
Poor wellbeing/WHO score ≤ 50%  
(ref. WHO score >50%) −0.04 (−0.09–0.02) 0.18 1.10 (0.89–1.38) 0.38
Table 2. Associations between nicotine metabolite ratio (NMR) and NMR status and participants 
characteristics. Adj. OR = adjusted odds ratio (adjusted for all variables shown); CI = confidence interval; 
HSI = Heaviness of Smoking Index; SES = socioeconomic status; ref. = reference category; *103 cases missing 
due to incomplete data.
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suggest that normal metabolisers should be actively encouraged to consider group support even if their natural 
preference may be for one-to-one options.
This study has a number of limitations. The cross-sectional design does not allow us to make causal or direc-
tional claims. Moreover, while we did include a variety of characteristics to investigate the association with 
NMR, a number of putative factors were not measured and some variables were only assessed with a single item. 
Although treatment site was controlled for in analysis, the extent to which the available resources and individual 
treatment providers within the region influenced treatment choice could not be determined directly. Yet, treat-
ment site is unlikely to have influenced NMR and therefore this analysis. Lastly, while the initial sample collected 
was largely representative of smokers seeking treatment in the UK, there were some marked demographic and 
treatment differences between those who provided a sample and those who did not.
Conclusions
Although significant associations between NMR and ethnicity, physical health and gender were identified, these 
sociodemographic, smoking, and health-related characteristics did not greatly influence variability in NMR and 
did not confound allocation to either slow or normal NMR status. This suggests that NMR status is relatively 
unrelated to these variables, functioning consistently across different populations, thus increasing its potential for 
use in clinical practice. The unexpected association of NMR status with behavioural support should be explored 
further in clinical trials and studies of real-world data. Given the association of NMR with pharmacotherapy 
efficacy, the finding that NMR status is currently not associated with pharmacotherapy choice suggests there is a 
need for providers to tailor smoking cessation therapies based on rate of nicotine metabolism as patients are not 
naturally selecting the option that has the highest potential efficacy for them.
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